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Abstract. This paper deals with the study of endothelio- and cardioprotective activity of 
arginase II selective inhibitor, the substance under the code ZB49-0010C in the model of 
hyperhomocysteine-induced endothelial dysfunction.  The results of the studies prove the 
presence in the arginase II selective inhibitor, the substance under the code ZB49-0010C, dose-
dependent endothelioprotective and cardioprotective activity, which expression increases with 
the increase in dose and is maximum at a dose of 10 mg/kg. 
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Nowadays, mortality from diseases of the 
cardiovascular system is a leader in the developed 
countries of the world. The main predictor of this 
group of diseases is endothelial dysfunction, which 
manifests itself in the impaired relaxation, 
antiagregation and other properties of the vascular 
endothelium [1, 2, 3, 4]. The key component of the 
pathogenesis of endothelial dysfunction (ED) is a 
deficit of endogenous nitric oxide. Nitric oxide (NO) 
is a leading humoral vascular relaxing factor 
produced by the endothelium [5, 6, 7]. In human and 
animal body, nitric oxide is synthesized from the 
amino acid L-arginine by the enzyme of endothelial 
NO-synthase (e-NOS). At the same time, arginase II 
catalyzes the transition of L-arginine to L-ornithine, 
which results in reduced content of a substrate for 
nitric oxide synthesis. That is why the selective 
blockade of arginase II will enhance the content of L-
arginine, which will increase the production of nitric 
oxide [8, 9]. Hyperhomocysteinemia has just recently 
been referred to the potential risk factors of 
cardiovascular diseases. Hyperhomocysteinemia may 
either be an independent factor for the development 
of endothelial dysfunction or strengthen an already 
existing endothelial injury [1, 10]. It is supposed that 
the effects of homocysteine are associated with its 
propensity to form disulfide bonds and ability of 
forming free radicals reacting with NO and reducing 
its biological activity. Moreover, NO synthesis is 
possibly disrupted [1, 10]. In this regard, the 
objective of our study was to investigate the 
endothelioprotective and cardioprotective activity of 
the selective inhibitor of arginase II in a wide range 
of doses upon simulation of hyperhomocysteine-
induced endothelial dysfunction. 
Materials and methods 
Experiments were performed in male albino 
Wistar rats weighing 200-250 g. For simulation of 
hyperhomocysteine-induced endothelial dysfunction, 
the methionine solution was administered 
intragastrically at a dose of 3 mg/kg/day for 7 days. 
Methionine solution for intragastric administration 
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was prepared with the use of stabilizator Tween 80 
and 1% starch mucilage [11, 12]. The experiment 
involved the following groups of animals: 1) intact – 
intragastric administration of a solubilizer Tween 80 
at a dose of 10 ml/kg for 7 days (n=10); 2) control - 
methionine intragastric administration at a dose of 3 
g/kg once a day for 7 days (n=10); 3) selective 
inhibitor of arginase II, ZB49-0010C substance 
intragastrically at a dose of 1 mg/kg once a day for 7 
consecutive days; 4) selective inhibitor of arginase II, 
ZB49-0010C substance intragastrically at a dose of 5 
mg/kg once a day for 7 consecutive days; 5) selective 
inhibitor of arginase II, ZB49-0010C substance 
intragastrically at a dose of 10 mg/g once a day for 7 
consecutive days. A selective inhibitor of arginase II, 
ZB49-0010C substance was administered for 7 days, 
30 minutes prior to methionine (n=10). 
On day 8 of the experiment, a catheter was 
inserted under anesthetisia (chloral hydrate 300 
mg/kg) into the left carotid artery to record blood 
pressure (BP); bolus administration of 
pharmacological agents was into the femoral vein. 
Hemodynamic parameters: systolic blood pressure 
(SBP), diastolic blood pressure (DBP) and heart rate 
(HR) were measured continuously with the use of a 
TSD104A sensor and the МР150 hardware and 
software system (BiopacSystem, Inc., USA). In 
addition to blood pressure measurements, a series of 
functional tests was performed with subsequent 
evaluation of changes in hemodynamic parameters 
(SBP, DBP, HR) in response to endothelium-
dependent vasodilatation (EDVD) and endothelium-
independent vasodilatation (EIVD) [13].  
The degree of endothelial dysfunction in 
experimental animal, as well as the degree of its 
correction with the studied medications was assessed 
by the estimated coefficient of endothelial 
dysfunction (EDC) [11, 12, 13, 14].  
To assess the myocardial functionality in 
animals under controlled respiration, the cavity of the 
left ventricle was catheterized and stress tests for 
adrenoreactivity and resistance load were performed 
[13, 15]. 
The level of stable NO metabolites (i.e., total 
concentration of nitrite and nitrate, Total NOx) was 
measured colorimetrically in rat plasma, and 
homocysteine concentration was determined with the 
biochemical analyzer Olympus AU 640. 
Statistical processing of the results of the study 
was performed by conventional methods, by 
calculating the average values (M) and the arithmetic 
mean error (±m). The significance of differences 
between the average values was determined by 
unpaired Student's t-criterion.  
Results 
Simulation of hyperhomocysteine-induced 
ED via intragastric administration of methionine at a 
dose of 3 g/kg resulted in a significant increase of 
EDC and homocysteine concentration in the blood 
plasma, as well as Total NOx reduction. While these 
indicators in intact animals were within the 
physiological norm. The effect of a selective inhibitor 
of arginase II, ZB49-0010C substance, on the initial 
values of EDC, homocysteine concentration and 
Total NOx in blood plasma in anesthetized rats upon 
modeling of hyperhomocysteine-induced ED is 
shown in Table 1.  
Table 1 
Indicators of endothelial dysfunction coefficient, Total NOx and homocysteine concentration in rat blood plasma upon 
modeling and correction of homocysteine-induced endothelial dysfunction by arginase II selective inhibitor  
(substance code ZB49-0010C) (n=10, М±m) 
 
Groups of animals 
EDC, 
(c.u.) 
Total NOx in blood plasma 
(μM) 
Homocysteine concentration 
in blood plasma 
(μM) 
Intact (TWIN 80, 10 ml/kg) 0.9 ± 0.1 119.0±2.6 8.3±0.3 
Methionine (3 g/kg) 3.3 ± 0.3* 68.9±4.3* 51.0±2.0* 
Methionine (3 g/kg)+ ZB49-0010C (1 
mg/kg) 
2.1±0.3** 79.6±2.6** 44.7±3.2** 
Methionine (3 g/kg)+ ZB49-0010C 
(5 mg/kg) 
1.8±0.2** 93.3±3.5** 36.6±2.9** 
Methionine (3 g/kg)+ ZB49-0010C 
(10 mg/kg) 
1.6±0.2** 113.8±3.7** 28.7±1.5** 
Note: EDC – endothelial dysfunction coefficient; Total NOx – the concentration of stable metabolites of nitric oxide 
in the blood plasma; * – significant difference as compared to the group of intact animals (p<0.05); ** – significant difference 
as compared to the group of animals treated with L-NAME (p<0.05). 
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It was found that daily administration of a selective 
inhibitor of arginase II, ZB49-0010C substance, upon 
modeling of hyperhomocysteine-induced ED, prevents 
the increase of EDC and the level of homocysteine in 
the blood plasma, as well as reduction of Total NOx. At 
the same time, these effects were dose-dependent, so, at 
a dose of 10 mg/kg a selective inhibitor of arginase II, 
substances under the code ZB49-0010C, the most 
strongly preventied an increase in EDC and the level of 
homocysteine in the blood plasma and reduction of 
Total NOx upon modeling of hyperhomocysteinemia-
induced ED, whereas at a dose of 1 mg/kg the impact 
on these indicators was insignificant, and at a dose of 5 
mg/kg the efficiency was intermediate between dose 1 
and 10 mg/kg (Table 1). 
To evaluate the effect of a selective inhibitor of 
arginase II, substances under the code ZB49-0010C, 
on functional contractility indices of left ventricular 
myocardium upon modeling of 
hyperhomocysteinemia-induced ED, the tests for 
adrenoreactivity and resistance load were conducted, 
the results of which are presented in Table 2. 
Table 2 
Effect of arginase II selective inhibitor (substances under the code ZB49-0010C) on functional contractility indices of 
left ventricular myocardium during stress tests upon modeling of hyperhomocysteinemia-induced ED (M±m, n=10) 
 
Group of animals 
Adrenoreactivity 
(mm Hg) 
Myocardial reserve level (%) 
Intact (TWIN 80, 10 ml/kg) 188.9±8.5 89.3 ± 4.2 
Methionine (3 g/kg) 239±3.8* 66.5 ± 4.4* 
Methionine (3 g/kg)+ ZB49-0010C  
(1 mg/kg) 
205.6±7.7** 79.2 ± 3.1 ** 
Methionine (3 g/kg)+ ZB49-0010C 
(5 mg/kg) 
204.2±4.8** 83.3  ± 5.0 ** 
Methionine (3 g/kg)+ ZB49-0010C 
(10 mg/kg) 
196.7±3.3** 89.5±4.9** 
Note: * – significant difference with the intact group (p<0.05); ** – significant difference with the control group 
(p<0.05). 
 
Test for adrenoreactivity was characterized by a 
pronounced increase in absolute values of LVP in the 
group of animals treated with methionine as compared 
to the group of intact animals. At the same time, daily 
administration of arginase II selective inhibitor, 
substance code ZB49-0010C, upon modeling of 
hyperhomocysteine-induced nitric oxide deficiency 
prevented increase in adrenoreactivity, with the most 
pronounced effect at a dose of 10 mg/kg. 
Test for resistance load established that arginase II 
selective inhibitor, substances code ZB49-0010C, 
prevented the decrease of myocardial contractility of the 
left ventricle from the 5th to the 25th second of the the 
ascending aorta compression.  The effect was dose-
dependent, since at a dose of 10 mg/kg there was the 
most pronounced prevention of decrease of myocardial 
reserve, whereas at a dose of 1 mg/kg the effect on 
myocardium contractile activity was minimal. 
Discussion 
Thus, the conducted studies have shown that a 
selective inhibitor of arginase II, substance under the 
code ZB49-0010C, has a pronounced dose-dependent 
endothelioprotective activity, which is expressed in 
the prevention of impaired relationship between 
endothelium-dependent and endothelium-
independent vasodilation and improvement of  
NO-synthesizing endothelial function upon modeling 
of hyperhomocysteine-induced ED. The said effects 
are most pronounced at a dose of 10 mg/kg. The 
study of the effect of a selective inhibitor of arginase 
II on myocardial contractility showed its pronounced 
dose-dependent cardioprotective effect, which 
manifests itself in a decrease in the sensitivity of the 
myocardium to adrenaline and maintenance of 
myocardial reserve during the test for resistance load. 
The said effects are also most pronounced at a dose 
of 10 mg/kg. These effects are primarily connected 
with increase in L-arginine bioavailability as the 
main substrate for nitric oxide synthesis, by blocking 
its biotransformation with arginase II.  
The obtained data are fully aligned with the 
results obtained by other authors [10, 14, 16, 17], and 
indicate the prospects of creating the arginase  
II-inhibiting drugs. The selectivity of the studied 
drug makes it more advantageous due to lack of 
impact on the urea metabolism [8, 9]. 
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